FDA Clearance Tracker · P030052
UROVYSION BLADDER CANCER KIT
Last checked: Nov 20, 2026Latest source record: Jan 24, 2005 (this decision)Source: openFDAMethods & limitations
Decided
Jan 24, 2005
Approved
Time to decision
411 days
Received Dec 10, 2003. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P030052
- Device name
- UROVYSION BLADDER CANCER KIT
- Applicant
- Abbott Molecular
- Applicant location
- Des Plaines, IL
- Received
- Dec 10, 2003
- Decided
- Jan 24, 2005
- Decision
- Approved
- Supplements
- 30 in FDA's data for this PMA. See them on the FDA record
Device type
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
APPROVAL FOR THE UROVYSION BLADDER CANCER KIT. THE DEVICE IS INDICATED FOR: THE UROVYSION BLADDER CANCER KIT (UROVYSION KIT) IS DESIGNED TO DETECT ANEUPLOIDY FOR CHROMOSOMES 3, 7, 17 AND LOSS OF THE 9P21 LOCUS VIA FLUORESCENCE IN SITU HYBRIDIZATION (FISH) IN URINE SPECIMENS FROM PERSONS WITH HEMATURIA SUSPECTED OF HAVING BLADDER CANCER. RESULTS FROM THE UROVYSION KIT ARE INTENDED FOR USE, IN CONJUNCTION WITH AND NOT IN LIEU OF CURRENT STANDARD DIAGNOSTIC PROCEDURES, AS AN AID FOR INITIAL DIAGNOSIS OF BLADDER CARCINOMA IN PATIENTS WITH HEMATURIA AND SUBSEQUENT MONITORING FOR TUMOR RECURRENCE IN PATIENTS PREVIOUSLY DIAGNOSED WITH BLADDER CANCER.
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- We could not check whether this was the first decision under its product code.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for Abbott Molecular
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Alinity m HCV510(k)
K252102 · Decided Sep 25, 2025 · 84 days after receipt
Device type: Assay, Hybridization And/Or Nucleic Acid Amplification For Detection Of Hepatitis C Rna,Hepatitis C Virus (MZP) · Laboratory Medicine & Pathology
- Alinity m HR HPVPMA supplement
P230003-S006 · Decided Sep 10, 2025 · 264 days after receipt · Panel Track
Device type: KIT, DNA DETECTION, HUMAN PAPILLOMAVIRUS (MAQ) · Laboratory Medicine & Pathology
K243489 · Decided Jul 28, 2025 · 258 days after receipt
Device type: Nucleic Acid Amplification Test For The Quantitation Of Epstein-Barr Virus (Ebv) Dna (QLX) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.